NRAS palmitoylation and oncogenic fitness

Abstract

In this issue of Blood, Zambetti et al validate that palmitoylation of mutant NRAS is essential for its oncogenic function by using a genetic mouse model. Their study highlights that the palmitoylation/depalmitoylation cycle is an attractive candidate for therapeutic intervention in hematologic malignancies with NRAS mutations.